SCM flexes formulation muscle for Mitovie

U.K.-based SCM Pharma is launching a formulation development capability in a deal with the University of Sunderland. SCM Pharma's move follows a two-year development project with Mitovie Pharma involving specialty drug formulation support for a lead candidate. The formulation effort is for a single-use product intended for treatment of accidental overdose.

SCM, which counts itself among the growing number of contract development and manufacturing organizations (CDMOs), will provide developmental services for such liquid formulations as emulsions and suspensions for parenteral, oral and topical administration. Stability and analytical testing are also part of the package, along with the capability to provide GMP formulation if required.

The CDMO's preclinical capability will be housed in formulation and analytical laboratories at the University of Sunderland's new science complex based near the clinical trial manufacturer's existing facility.

As SCM trumpets the expansion of its traditional manufacturing production offerings into such development services as formulation, it's joined by other CDMOs sensing the opportunity. Recent among these is Patheon, which announced last week investment and expansion into early drug development services.

- see the release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.